Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | GSK3B | P49841 | 2/20 | 0.55 |
| ▸ | CES2 | O00748 | 2/20 | 0.52 |
| ▸ | CES1 | P23141 | 2/20 | 0.52 |
| ▸ | VNN1 | O95497 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9541276 | 0.89 | CES2 (0.61) | SRD5A2CES2CES1HPGDALDH1A1 | |
| SCHEMBL187134 | 0.89 | CES2 (0.61) | SRD5A2CES2CES1HPGDALDH1A1 | |
| SCHEMBL11464002 | 0.83 | SRD5A2 (0.61) | SRD5A2MAPK1GSK3BCES2CES1 | |
| SCHEMBL9065883 | 0.83 | SRD5A2 (0.61) | SRD5A2MAPK1GSK3BCES2CES1 | |
| SCHEMBL7015547 | 0.82 | SRD5A2 (0.47) | SRD5A2MAPK1GSK3BCES2CES1 | |
| SCHEMBL2931832 | 0.82 | CES2 (0.51) | CES2CES1VNN1ALOX15L3MBTL1 | |
| SCHEMBL1766 | 0.82 | — | — | |
| SCHEMBL9065412 | 0.82 | SRD5A2 (0.80) | SRD5A2MAPK1GSK3BCES2CES1 | |
| SCHEMBL51827 | 0.82 | SRD5A2 (0.80) | SRD5A2MAPK1GSK3BCES2CES1 | |
| SCHEMBL10697158 | 0.82 | SRD5A2 (0.80) | SRD5A2MAPK1GSK3BCES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1559422-B1 | RECEPTOR FUNCTION CONTROLLING AGENT | TAKEDA PHARMACEUTICAL (JP) | 2014-04-30 | — | — | EP | disclosed |
| EP-2385032-A1 | GPR40 Receptor function regulator | Takeda Pharmaceutical Company Limited (JP) | 2011-11-09 | — | — | EP | disclosed |
| US-7960369-B2 | Receptor function regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-14 | — | — | US | disclosed |
| EP-2121616-B1 | NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS | CAMPIANI GIUSEPPE (IT) | 2010-09-15 | — | — | EP | disclosed |
| US-20100093726-A1 | NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS | GIUSEPPE CAMPIANI (IT) | 2010-04-15 | — | — | US | disclosed |
| EP-2121616-A1 | NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS | Campiani, Giuseppe (IT) | 2009-11-25 | — | — | EP | disclosed |
| US-7601868-B2 | Such as 4-(cyclopropylmethoxy)-N-(2-{4-[1-(1-pyrrolidinyl)ethyl]phenyl}ethyl)benzamide having melanin-concentrating hormone antagonistic action, for prophylaxis and/or treatment of obesity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-13 | — | — | US | disclosed |
| US-20090012093-A1 | Receptor Function Regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-08 | — | — | US | disclosed |
| WO-2008101891-A1 | NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS | CAMPIANI GIUSEPPE (IT) | 2008-08-28 | — | — | WO | disclosed |
| WO-2007104696-A1 | ANTIMALARIAL AGENTS HAVING POLYAROMATIC STRUCTURE | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2007-09-20 | — | — | WO | disclosed |
| EP-0742202-A2 | Benzophenone hydrazone derivatives as insecticides | NIHON BAYER AGROCHEM K.K. (JP) | 1996-11-13 | — | — | EP | disclosed |
| WO-1996033168-A1 | BENZYLSULFIDE DERIVATIVE, PROCESS FOR ITS PRODUCTION AND PESTICIDE | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 1996-10-24 | — | — | WO | disclosed |
| EP-0733633-A1 | Heterocyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-09-25 | — | — | EP | disclosed |
| EP-0665223-A1 | Antitumor agent, novel 3(2H)-pyridazinone derivatives and their preparation | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-08-02 | — | — | EP | disclosed |
| EP-0333291-B1 | Benzophenone derivatives | OCTEL CHEM LTD (GB) | 1994-08-10 | — | — | EP | disclosed |
| EP-0151529-B1 | 5-(AMINO OR SUBSTITUTED AMINO)-1,2,3-TRIAZOLES | MERCK & CO. INC. (US) | 1991-09-18 | — | — | EP | disclosed |
| US-4948819-A | Benzophenone quaternary ammonium linked (meth)acrylates, photocurable and photocured products, and method of coating | WARD BLENKINSOP & COMPANY LIMITED (GB) | 1990-08-14 | — | — | US | disclosed |
| EP-0333291-A2 | Benzophenone derivatives | OCTEL CHEMICALS LIMITED (GB) | 1989-09-20 | — | — | EP | disclosed |
| US-4590201-A | ANTICOCCIDIAL AGENT FOR ANIMALS PARTICULARLY FOR POULTRY | MERCK & CO., INC. (US) | 1986-05-20 | — | — | US | disclosed |
| EP-0151529-A2 | 5-(Amino or substituted amino)-1,2,3-triazoles | MERCK & CO. INC. (US) | 1985-08-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093726-A1 | NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS | QTRT1, QTRT2, IL4I1 | SRD5A2 4696/4885MAPK1 2945/4885GSK3B 4033/4885 |
| US-20090012093-A1 | Receptor Function Regulator | GPR119, GIPR, INSR | SRD5A2 1727/4885MAPK1 1667/4885GSK3B 4750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.